A life sciences company developing innovative solutions for smoking and vaping cessation.
Meet the DitchPen®.
The DitchPen®, a prescription-based medical inhaler, combines nicotine replacement therapy (NRT) with a user-friendly digital app to provide a personalized, gradual, and automated smoking and vaping cessation program.
The Problem
Tobacco Use Disorder (TUD) remains a major global health challenge. Smoking, the leading cause of preventable illness and death, is a key risk factor for cardiovascular disease, cancer, respiratory disease, and diabetes. Globally, 1.25 billion people smoke, 82 million use e-cigarettes, and two-thirds of smokers want to quit.
Yet, existing Nicotine Replacement Therapies (NRT) have low success rates of 10–15%, as they fail to replicate the rapid nicotine delivery of smoking, overlook psychological triggers, and adopt a one-size-fits-all approach, leading to high relapse rates.
E-cigarettes, while popular, often result in users transferring their dependence, with quality and safety concerns further limiting their reliability. Clinicians remain hesitant to recommend them, highlighting the need for more effective cessation solutions.
Our Solution
Ditch's mission is to address this critical gap by leveraging its expertise in engineering, pharmacology, and psychology to develop:
A drug-device combination inhaler that:
Utilizes a dual aerosolization system, supported by 17 granted patents.
Precisely delivers nicotine through an active and inactive solution.
Gradually reduces nicotine intake over 12 weeks with a personalized approach.
A companion digital therapeutic that:
Tracks nicotine consumption and provides real-time feedback.
Delivers evidence-based interventions to address both physical and psychological dependence.
Offers comprehensive cessation support, including 150+ educational modules.